Commercialized a highly effective skin cancer scanning device

Initial orders from its Brazilian distribution partner could result in $8M of hardware sales over the next 2 years

Sponsored
Message: VIDEO: MedX (MDX:TSXV) Telemedicine Platform For Skin Cancer Gets Record Order, Set To Generate Millions In 2020

VIDEO: MedX (MDX:TSXV) Telemedicine Platform For Skin Cancer Gets Record Order, Set To Generate Millions In 2020

posted on Jun 17, 2020 04:07PM
MedX (MDX:TSXV) is the "overnight 5-year success story" that most retail investors have never heard about ... but that is all about to change in 2020, a year that is set to dwarf the $860,000 in revenue MDX generated in 2019.
 
What do they do?  In layman's terms, they've combined their skin cancer scanning device with proprietary software to create a telemedicine platform focused on skin cancer.  In essence, you scan a troubling spot on your body and within 72 hours you can have both a prognosis and treatment completed - god forbid.
 
Sounds like a cool idea but does it work?  Glad you asked.  The platform was proven through a proof-of-concept trial in Norway where 109 pharmacies captured 80,000 scans and found 860 cases of melanoma.
 
2020 is shaping up to be both the Company's best year ever and the beginning of something potentially great.  Why?
 
1.  MDX signed an exclusive distribution deal that led to the Company receiving its biggest order in history - 500 units.  With much more expected to come due to minimum annual sales requirements.
2.  MDX just did the same thing in Mexico on Monday.
 
Mike Druhan, Vice President of Corporate Development, believes more countries are set to follow.  We'd love to tell you more but trust us when we tell you that we've saved the best for the interview.
 
Telemedicine is going to be a monster, disruptive industry this decade and MDX has the early upper hand in the world of skin cancer.
 
Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.
 
 
Share
New Message
Please login to post a reply